Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 176 participants.

Also called NCT07055516

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 176 participants (enrolled count) (from the registry)
Sponsor
NodThera Ltd. (a Rezera company) (from the registry)
Registry
  • NCT NCT07055516
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07055516. Randomized; triple masking; primary purpose treatment. Start 2025-05-08 (actual); primary completion 2026-05-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes Mellitus
Acronym
RESOLVE-1
Condition
Obesity and Type 2 Diabetes
Intervention (Drug)
NT-0796
Intervention (Drug)
Placebo
Lead sponsor
NodThera Ltd. (a Rezera company) (class: industry)

Record details

Record id
cardio:ct-nct07055516
Content hash
ff306ebfa918cc1526210884417570cd52927a7a4a334e599028d02351a62b62